Xeloda for Metastatic Breast Cancer

An Oral Chemotherapy Option

Xeloda is the brand name for capecitabine. It is an oral chemotherapy (chemo) medication that treats metastatic breast cancer. Metastatic means the cancer has spread to other parts of the body.

As a breast cancer chemo pill, Xeloda may be given alone or combined with other anti-cancer medications. It is often prescribed after other chemotherapy does not work or when the cancer recurs, or returns. Xeloda can be used to treat colorectal (CRC) cancers too.

This article discusses Xeloda's mechanism of action (how it works), along with its uses, dosage, side effects, risks, and contraindications. It offers information about finding Xeloda and its costs.

Young female cancer patient meets with doctor
FatCamera / Getty Images


Xeloda has been approved to treat metastatic breast cancer that has not responded to previous treatment, or when previous treatment has stopped working. Xeloda may be given alone or in combination with another medication such as Taxotere (docetaxel) or Tykerb (lapatinib).

Previous treatments include surgery, radiation, chemotherapy, or endocrine (hormone) therapy originally prescribed based on your type of breast cancer. For example, Xeloda is typically given when you have not responded to other chemotherapy medications such as Taxol (paclitaxel), Adriamycin (doxorubicin), or Taxotere (docetaxel).

Xeloda is considered for the following types of metastatic breast cancer:

  • HER2-negative
  • HER2-positive
  • Triple-negative
  • Hormone receptor-negative
  • Hormone receptor-positive cancer (if endocrine therapy stops working)

Your healthcare team may consider Xeloda in specific circumstances. They include:

  • Before surgery to shrink a tumor (neoadjuvant treatment)
  • After surgery to kill remaining cancer cells (adjuvant treatment)
  • When other treatment does not work
  • When cancer returns
  • For palliative treatment (to relieve symptoms when cancer is incurable)

Before Taking

Your healthcare team will evaluate your case to see if Xeloda is a good fit for you. This depends on the type, stage, and size of the cancer. It is also based on where the cancer has spread, previous treatment, and how you responded to that treatment. 

Before starting Xeloda, you will receive education about the drug and how side effects can be managed. Your healthcare provider may order baseline blood tests or an electrocardiogram (ECG or EKG).

Is There a Xeloda Generic?

Yes, Xeloda is the brand name for capecitabine. The Food and Drug Administration approved the Xeloda generic in 2013. It's made the drug more widely available. The generic cost is typically lower, but it will vary widely depending on factors like your insurance coverage or how you buy it. The cost per month of capecitabine was $1,518 in 2014, according to data published through 2019 by the Memorial Sloan Kettering Cancer Center. The drug company that makes the Xenoda brand also has a financial aid program.

How It Works

Xeloda kills cancer cells by imitating part of a cancer cell's genes. This makes the cell die before it can divide, which slows or stops cancer from growing. It is classified as an antimetabolite.


Efficacy refers to the effectiveness of a medicine. Studies show that Xeloda is an effective medication in the treatment of breast cancer. It helps to decrease the chance of cancer returning and prolongs survival for those with metastatic breast cancer.

This includes giving it alone, when combined with standard chemotherapy, as a post-surgical treatment, or in combination with either Taxotere or Tykerb.

While studies show that it can be effective for many people, Xeloda may not be as effective as some other drugs, and adding it to other chemotherapy drugs may increase the risk of side effects.

Dosage and Schedule

Xeloda is an oblong, peach-colored pill given in either 150 milligram (mg) or 500 mg dosages. It's generally taken twice a day, ideally about 30 minutes after a meal and with plenty of water.

The pills should not be crushed, chewed, or dissolved. If you miss a dose, you should wait until your next dose is due and take only that. You should not take an extra dose to compensate for the missed dose.

It's taken on a cyclical dosage schedule that's two weeks on, one week off, then two weeks on. Your healthcare provider will decide how long you'll stay on this cycle.

Side Effects

Common side effects of Xeloda include:

  • Diarrhea
  • Nausea
  • Vomiting
  • Oral mucositis (sores in your mouth, tongue, and throat)
  • Stomach pain
  • Low appetite
  • Dehydration
  • Skin rash or dry, itchy skin
  • Dizziness
  • Fatigue
  • Headache
  • Swelling of the feet, ankles, or hands
  • Neuropathy (tingling of fingers and toes)
  • Weight loss

When taking Xeloda, try to stay hydrated by drinking more water and avoiding alcohol or caffeine, as these can dehydrate you. Ideally, you should get about 90 ounces of water per day. This includes water you get from food.

If you experience mouth or tongue sores, replace your usual toothbrush with a soft-bristled kind. There are also many other measures and food choices you can make to reduce this symptom.

If you experience dizziness, plan to take it easy. If you're extremely nauseous, your healthcare provider may recommend anti-nausea medications to help you through.

The side effects of Xeloda may be different if you are taking it along with Taxotere or other chemotherapy drugs. Be sure to report all of your side effects to your healthcare provider. Note the dates and times they occur and the severity of each symptom.

Call your healthcare provider and stop taking Xeloda immediately if you have these symptoms:

  • Severe diarrhea
  • Severe vomiting
  • Painful sores in your mouth and tongue
  • Fever


Taking Xeloda with blood thinners such as Coumadin (warfarin) can cause your blood to thin more. This puts you at risk of bleeding more than usual, even with minor cuts.

Tell your healthcare provider if you take blood thinners. They may want to prescribe a lower dose of Xeloda or monitor your bloodwork more frequently.

To avoid common scrapes and scratches, consider wearing gloves while doing housework or gardening, protect your skin in cool weather, and switch to an electric razor.

Drug Interactions and Supplements

Coumadin and other blood thinners are drugs that interact with Xeloda. It's important to note that some nutritional supplements may also work as blood thinners, and you should talk to your oncology team before taking them.

In those 80 years old or older, Xeloda may cause more diarrhea, nausea, and vomiting than in younger people.

Hand-foot syndrome can occur with Xeloda. It often starts with darkening of the palms of the hands and soles of the feet. As it progresses, it can become more like a sunburn. There are several things you can do to help prevent this including keeping your hands and feet cool, wearing good shoes, and not going barefoot.

Xeloda can cause photosensitivity, which means you may get a sunburn more easily. Consider the following precautions to help protect your skin:

  • Avoid sun exposure if possible
  • Use a good sunscreen
  • Cover up using UV clothes, hats, or an umbrella

Since Xeloda can make you more susceptible to infections, it’s best to avoid situations that might put you at risk, such as crowded places and visiting ill friends.


If you are in any of the following categories, your healthcare team may adjust your dose, monitor you more closely, or choose another medication:

  • Pregnant or breastfeeding: Xeloda can cause harm to a baby during pregnancy. If you are of childbearing years, your healthcare provider will most likely have you take a pregnancy test before starting Xeloda. If you are pregnant, breastfeeding, or plan to get pregnant, talk to your provider about different treatment options.
  • 65 or older: If you are 65 or older, the chance of having side effects or adverse reactions increases. Your healthcare team may want to monitor you more closely while you are taking this medication.
  • Liver or kidney insufficiency: For those with hepatic (liver) or renal (kidney) insufficiency, your healthcare provider may choose to give a lower starting dose and monitor you closely.
  • Pediatric: The safety and effectiveness of Xeloda have not been established for children.


You should not take Xeloda if you have the following:

  • Severe renal impairment (creatinine clearance below 30 mL/min) 
  • Hypersensitivity to Xeloda, to any of its components, or to Carac, Tolak, Efudex, Fluoroplex (5-fluorouracil or 5-FU)


Xeloda (capecitabine) is an oral chemotherapy medication that treats metastatic breast cancer. It can be given alone or in combination with other chemotherapy medications. Typically, it is given when other treatment does not work or stops working. It can also be used for colon and rectal cancers.

Xeloda kills cancer cells by imitating part of the cells' genes. This stops or slows the cancer from growing. Side effects include diarrhea, nausea, vomiting, mouth sores, hand and foot syndrome, fatigue, and more. If any of these become severe, or you develop a fever, call your healthcare provider. 

Those with severe kidney impairment or hypersensitivity to Xeloda or any of its components should not take this medication.

Frequently Asked Questions

  • How long do you take Xeloda for breast cancer?

    Xeloda is taken in three-week rotating cycles of 14 days on and seven days off of medication. Your healthcare team will decide how long you will be on the medication based on your case. In some cases, they may order eight cycles. Or you may stay on it until it is no longer helpful or causes significant side effects. 

  • How long does Xeloda stay in your system?

    Xeloda has a short half-life of about 45 minutes. It takes five half-lives for the medication to leave your body, which is four hours for this medication. However, the effects of the medication last longer and side effects can occur later.

  • Can Xeloda shrink tumors?

    Yes, Xeloda slows or stops cancer from growing by imitating part of a cancer cell's genes, causing the cell to die before it can divide.

  • What is the success rate of Xeloda?

    Studies show that after five years the overall survival rate was 89.2% for women treated with Xeloda compared to 83.6% for women who were not treated with it. And 74.1% had remained cancer-free with Xeloda after five years, compared to 67.7% of those who didn’t receive it.

Originally written by
Pam Stephan
Pam Stephan is a breast cancer survivor.
Learn about our editorial process
17 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. U.S. Food and Drug Administration. XELODA (capecitabine) tablets [package insert].

  2. Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysisEur J Cancer. 2017;84:141-148. doi:10.1016/j.ejca.2017.07.024

  3. Breastcancer.org. Xeloda.

  4. American Cancer Society. Treatment of triple-negative breast cancer.

  5. Breastcancer.org. Xeloda improves survival in women with early-stage, her2-negative disease who have residual disease after chemotherapy before surgery.

  6. Breastcancer.org. One year of low-dose Xeloda after surgery for triple-negative breast cancer seems to reduce recurrence risk.

  7. Breastcancer.org. FDA approves Nerlynx for HER2-positive metastatic breast cancer.

  8. Cochrane Review. Benefits of capecitabine in hormone receptor-positive compared to hormone receptor-negative breast cancer.

  9. Colorectal Cancer Alliance. Generic Xeloda Approved.

  10. Memorial Sloan Kettering Cancer Center. Price & Value of Cancer Drug.

  11. Natori A, Ethier J, Amir E, Cescon D. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. Eur J Cancer. 2017;77:40-47. doi:10.1016/j.ejca.2017.02.024

  12. Madden R, Kosari S, Peterson G, Bagheri N, Thomas J. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review. Int J Clin Parmacol Ther. 2018;56(2):72-80. doi:10.5414/CP203123.

  13. Memorial Sloan Kettering Cancer Center. Capecitabine.

  14. Harvard School of Public Health. The importance of hydration.

  15. Caprez J, Rahim U, Ansari A, Lodhi M, Rahim M. Hyperpigmentation with capecitabine: Part of hand-foot syndrome or a separate entity? Cureus. 2018;10(3):e2397. doi:10.7759/cureus.2397

  16. Lembo S, Raimondo A, Conti V, Venturini M. Photosensitivity and cancer immune‐targeted therapies. Photodermatol Photoimmunol Photomed. 2020;36(3):172-178. doi:10.1111/phpp.12533.

  17. Masuda, N, Lee, S, Ohtani S et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine. 2017;376:2147-2159. doi 10.1056/NEJMoa1612645.

Additional Reading